22:08 , Dec 1, 2017 |  BC Week In Review  |  Company News

Acorda cashes out on Selincro royalties

H. Lundbeck A/S (CSE:LUN) will pay Acorda Therapeutics Inc. (NASDAQ:ACOR) $13 million to eliminate milestone and royalty payments tied to ex-U.S. sales of Selincro nalmefene. Lundbeck licensed the alcohol dependence drug from BioTie Therapies Corp.,...
00:02 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

Acorda discontinues PD candidate Tozadenant

Acorda Therapeutics Inc. (NASDAQ: ACOR) discontinued development of Parkinson's disease candidate tozadenant (SYN115) "based on new information" related to cases of agranulocytosis disclosed on Nov. 15 that were possibly related to tozadenant and in some...
23:22 , Nov 30, 2017 |  BC Week In Review  |  Clinical News

Otsuka submits Japanese NDA for nalmefene to treat alcohol dependence

In October, Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) submitted a Japanese NDA for nalmefene to treat alcohol dependence. Otsuka and H. Lundbeck A/S (CSE:LUN) co-developed nalmefene for alcohol dependency in Japan. It is marketed as...
17:54 , Nov 20, 2017 |  BC Extra  |  Clinical News

Acorda discontinues PD candidate tozadenant

Acorda Therapeutics Inc. (NASDAQ: ACOR) discontinued development of Parkinson's disease candidate tozadenant (SYN115) "based on new information" related to cases of agranulocytosis disclosed last week that were possibly related to tozadenant and in some cases...
05:04 , Nov 17, 2017 |  BC Week In Review  |  Clinical News

Acorda discloses safety concerns for PD candidate tozadenant

Acorda Therapeutics Inc. (NASDAQ:ACOR) disclosed cases of agranulocytosis that were possibly related to treatment with Parkinson's disease candidate tozadenant (SYN115) and in some cases associated with sepsis and death. Among about 890 patients who received...
23:03 , Nov 15, 2017 |  BC Extra  |  Clinical News

Acorda falls on tozadenant safety concerns

Acorda Therapeutics Inc. (NASDAQ:ACOR) lost $11.20 (40%) to $17 on Wednesday after disclosing cases of agranulocytosis that were possibly related to treatment with Parkinson's disease candidate tozadenant (SYN115) and in some cases associated with sepsis...
07:16 , Jul 29, 2017 |  BioCentury  |  Finance

Show us your shorts

Absent any data showing a sustained impact of manipulative short selling on biotech valuations or their ability to raise capital, it is difficult to discern what direct benefit biotech companies would gain from BIO ’s...
19:42 , Apr 7, 2017 |  BC Week In Review  |  Company News

Acorda patent challenge and restructuring news

The U.S. District Court for the District of Delaware invalidated four of the five Orange Book-listed patents protecting Acorda’s multiple sclerosis drug Ampyra dalfampridine on grounds of obviousness. Acorda said it plans to appeal the...
08:00 , Jan 25, 2016 |  BC Week In Review  |  Company News

Biotie, Acorda deal

Biotie Therapies Corp. (HSE:BTH1V;NASDAQ:BITI), Turku, Finland   Acorda Therapeutics Inc. (NASDAQ:ACOR), Ardsley, N.Y.   Business: Neurology   Acorda will acquire Biotie for EUR23.57 per ADS in cash .The companies said the deal values Biotie at...
02:10 , Jan 20, 2016 |  BC Extra  |  Top Story

Acorda adds to PD portfolio with Biotie takeout

Acorda Therapeutics Inc. (NASDAQ:ACOR) will acquire Biotie Therapies Corp. (HSE:BTH1V; NASDAQ:BITI) for about $363 million in cash. The deal gives Acorda two clinical stage programs for Parkinson's disease, including oral selective adenosine A2A receptor (...